# Keros Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Keros Therapeutics, Inc.). ## Overview Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling. Its pipeline is centered on KER-065 for neuromuscular disease and elritercept for cytopenias such as anemia and thrombocytopenia in MDS and myelofibrosis. ## Products & services • KER-065 (rinvatercept) for neuromuscular diseases • Elritercept (KER-050) for cytopenias in MDS and myelofibrosis • Cibotercept discovery/development program • Research collaborations and licensing of intellectual property • Clinical development and manufacturing management via CMOs - **Clinical-stage product candidates** (0%) — Protein therapeutics in human trials, including KER-065 and elritercept. - **Discovery and preclinical programs** (0%) — Earlier-stage programs such as cibotercept and related pipeline research. - **Collaboration and license revenue** (100%) — Upfront, milestone, and potential royalty income from partners such as Takeda. - **Contracted manufacturing and supply chain services** (0%) — CMO-based manufacturing, labeling, packaging, and distribution for clinical supply. - KER-065 (rinvatercept) for neuromuscular diseases - Elritercept (KER-050) for cytopenias in MDS and myelofibrosis - Cibotercept discovery/development program - Research collaborations and licensing of intellectual property - Clinical development and manufacturing management via CMOs ## Customers Keros does not sell approved commercial products; its current counterparties are pharmaceutical partners and clinical trial participants. Revenue today comes from collaboration and licensing arrangements, most notably the Takeda license for elritercept outside mainland China, Hong Kong, and Macau. If approved in the future, its end customers would be patients with neuromuscular disorders, MDS, and myelofibrosis, with commercialization likely through partners or a self-built sales force. - **Pharmaceutical collaboration partners** (primary) — Partners such as Takeda pay upfronts, milestones, and future royalties to access Keros assets and development rights. - **Clinical trial patients and investigators** (primary) — Sites and patients participate in trials for KER-065, elritercept, and other programs to generate clinical data. - **Future specialty-care patients** (emerging) — Patients with neuromuscular disease, MDS, or myelofibrosis would be the eventual users if products are approved. - **Healthcare providers and payers** (emerging) — Hospitals, specialists, and reimbursement systems would influence adoption and access after commercialization. - Takeda and other licensing partners fund development and may commercialize assets - Clinical trial investigators and sites run KER-065 and elritercept studies - Patients with DMD and other neuromuscular diseases are the KER-065 target group - Patients with MDS and myelofibrosis are the elritercept target group - Future payers and providers would matter if products reach market ## Geography Keros is headquartered in Lexington, Massachusetts and operates as a U.S.-based development company. Its commercial geography is currently defined by licensing scope rather than product sales: Takeda has worldwide rights outside mainland China, Hong Kong, and Macau for elritercept. Manufacturing and clinical supply are outsourced to CMOs, so operational exposure is tied to third-party supply chains rather than owned plants. - Headquartered in Lexington, Massachusetts, United States - Takeda license covers worldwide rights outside mainland China, Hong Kong, and Macau - No approved product sales yet, so geography is driven by trials and partnerships - Clinical and preclinical supply is outsourced to CMOs - Supply-chain concentration matters because there is no redundant supply arrangement ## Strategy Keros is focused on advancing its clinical pipeline while using partnerships to fund development and broaden reach. The Takeda agreement is strategically important because it monetizes elritercept ex-China while preserving upside through milestones and royalties. Near term, the company is prioritizing clinical execution, manufacturing readiness, and intellectual property protection ahead of any future commercialization. - **Advance KER-065 clinical development** (short-term) — The program is a key value driver and needs human data to support future partnering or approval. - **Execute the Takeda collaboration for elritercept** (short-term) — The deal provides non-dilutive capital and external development capacity while preserving royalty upside. - **Prepare for eventual commercialization** (medium-term) — If any candidate is approved, Keros will need manufacturing, sales, and distribution capabilities. - **Expand and defend intellectual property** (medium-term) — Patent and know-how protection are central to exclusivity and partnering leverage in biotech. - Advance KER-065 into Phase 2 and expand its clinical evidence base - Progress elritercept through late-stage development with Takeda support - Use collaboration revenue to fund R&D and reduce financing pressure - Protect and extend the TGF-β biology and protein-therapeutics IP portfolio - Build CMO and regulatory readiness for potential commercialization ## Risks Keros remains a development-stage biotech with no approved products, so its value depends on clinical success, regulatory outcomes, and access to capital. The company also relies on third-party manufacturers and a small number of collaboration agreements, which creates operational and counterparty concentration risk. Like other biotech firms, it faces binary trial risk, pricing/reimbursement uncertainty, and intense competition from larger companies with deeper resources. - **Clinical development failure** [critical] — KER-065 and elritercept are still in clinical trials, so efficacy or safety setbacks could eliminate value. - **Need for additional capital** [high] — The company has a limited operating history and expects substantial ongoing R&D spending. - **Manufacturing and supply-chain concentration** [high] — Clinical and future commercial supply depend on CMOs with no redundant supply arrangements in place. - **Partner concentration and contract dependence** [medium] — A meaningful portion of revenue is tied to the Takeda collaboration and its milestone/royalty path. - **Competitive and regulatory pressure** [high] — Large biotech and pharma companies can outspend Keros and regulatory requirements may change. - No approved products means continued dependence on clinical and regulatory success - Additional capital may be needed before commercialization - Trial failures or safety issues could materially delay or stop programs - CMO dependence creates supply and quality risk without redundant sourcing - Competition is intense in TGF-β-related and hematology/neuromuscular markets - IP disputes or licensing issues could increase costs or limit commercialization ## Accounting Revenue is driven by collaboration and license accounting, especially the Takeda agreement, so timing of milestone and service revenue can materially affect quarterly results. Stock-based compensation is also important because the company grants options and RSUs broadly, and fair-value assumptions can move reported expenses. As a clinical-stage biotech, Keros must also watch estimates around R&D accruals, contingent obligations, and any future impairment or valuation judgments tied to licenses and intangibles. - **Revenue recognition for collaboration and license agreements** — Takeda upfront, service revenue, and future milestones - **Stock-based compensation** — Reported R&D and G&A expense - **Clinical trial accruals and estimates** — R&D expense and liabilities - **Potential impairment and valuation judgments** — Future balance sheet and earnings volatility - ASC 606 collaboration revenue timing affects quarter-to-quarter results - Takeda upfront and milestone payments can create lumpy revenue recognition - Stock-based compensation depends on Black-Scholes assumptions and vesting - R&D accruals and clinical trial estimates affect expense timing - Future license or intangible asset valuations could require impairment testing --- *Last updated: 2026-04-28T20:20:12.645870+00:00*